Piper Sandler analyst Jessica Tassan raised the firm’s price target on Evolent Health to $51 from $44 and keeps an Overweight rating on the shares. The analyst assume the Magellan Specialty Health acquisition closes in the first half of 2023 and introduced pro forma estimates. She views Evolent’s acquisitions as "transformational."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EVH: